LLMC 2020 | IKEMA trial update: Isatuximab in MM
Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, CA, gives an update on the Phase III IKEMA trial (NCT03275285) in patients with multiple myeloma (MM). The trial compares the novel CD38 monoclonal antibody isatuximab in combination with carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapse and/or refractory MM patients. Results so far have found that progression-free survival is drastically improved when isatuximab is added to the carfilzomib, dexamethasone combination opening up the potential to treat patients in early relapse with a monoclonal antibody and proteosome inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Consultant for Amgen, BMS, Karyopharm, Janseen, Sanofi and Takeda
